Myriad Genetics, Inc.
Myriad Genetics, Inc. (MYGN) Stock Competitors & Peer Comparison
See (MYGN) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MYGN | $4.38 | -1.57% | 403.7M | -3.91 | -$1.12 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.58% |
| TMO | $484.96 | +1.39% | 183.1B | 28.00 | $17.32 | +0.34% |
| DHR | $202.94 | -1.24% | 145.3B | 43.09 | $4.71 | +0.58% |
| IDXX | $566.50 | +0.23% | 45.6B | 52.46 | $10.80 | N/A |
| A | $119.54 | -0.53% | 34B | 29.44 | $4.06 | +0.82% |
| IQV | $197.76 | -0.71% | 33.6B | 28.68 | $6.89 | N/A |
| MTD | $1,261.03 | -0.23% | 26.2B | 31.47 | $40.07 | N/A |
| NTRA | $138.00 | -0.65% | 18.8B | -93.88 | -$1.47 | N/A |
| DGX | $167.85 | -0.42% | 18.8B | 20.14 | $8.34 | +1.84% |
Stock Comparison
MYGN vs DHR-PB Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, MYGN is priced at $4.38, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, MYGN's ROE is -0.14%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, MYGN is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check DHR-PB's competition here
MYGN vs TMO Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, TMO has a market cap of 183.1B. Regarding current trading prices, MYGN is priced at $4.38, while TMO trades at $484.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas TMO's P/E ratio is 28.00. In terms of profitability, MYGN's ROE is -0.14%, compared to TMO's ROE of +0.13%. Regarding short-term risk, MYGN is more volatile compared to TMO. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check TMO's competition here
MYGN vs DHR Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, DHR has a market cap of 145.3B. Regarding current trading prices, MYGN is priced at $4.38, while DHR trades at $202.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas DHR's P/E ratio is 43.09. In terms of profitability, MYGN's ROE is -0.14%, compared to DHR's ROE of +0.07%. Regarding short-term risk, MYGN is more volatile compared to DHR. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check DHR's competition here
MYGN vs IDXX Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, IDXX has a market cap of 45.6B. Regarding current trading prices, MYGN is priced at $4.38, while IDXX trades at $566.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas IDXX's P/E ratio is 52.46. In terms of profitability, MYGN's ROE is -0.14%, compared to IDXX's ROE of +0.57%. Regarding short-term risk, MYGN is more volatile compared to IDXX. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check IDXX's competition here
MYGN vs A Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, A has a market cap of 34B. Regarding current trading prices, MYGN is priced at $4.38, while A trades at $119.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas A's P/E ratio is 29.44. In terms of profitability, MYGN's ROE is -0.14%, compared to A's ROE of +0.19%. Regarding short-term risk, MYGN is more volatile compared to A. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check A's competition here
MYGN vs IQV Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, IQV has a market cap of 33.6B. Regarding current trading prices, MYGN is priced at $4.38, while IQV trades at $197.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas IQV's P/E ratio is 28.68. In terms of profitability, MYGN's ROE is -0.14%, compared to IQV's ROE of +0.20%. Regarding short-term risk, MYGN is more volatile compared to IQV. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check IQV's competition here
MYGN vs MTD Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, MTD has a market cap of 26.2B. Regarding current trading prices, MYGN is priced at $4.38, while MTD trades at $1,261.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas MTD's P/E ratio is 31.47. In terms of profitability, MYGN's ROE is -0.14%, compared to MTD's ROE of +1.21%. Regarding short-term risk, MYGN is more volatile compared to MTD. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check MTD's competition here
MYGN vs NTRA Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, NTRA has a market cap of 18.8B. Regarding current trading prices, MYGN is priced at $4.38, while NTRA trades at $138.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas NTRA's P/E ratio is -93.88. In terms of profitability, MYGN's ROE is -0.14%, compared to NTRA's ROE of -0.18%. Regarding short-term risk, MYGN is more volatile compared to NTRA. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check NTRA's competition here
MYGN vs DGX Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, DGX has a market cap of 18.8B. Regarding current trading prices, MYGN is priced at $4.38, while DGX trades at $167.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas DGX's P/E ratio is 20.14. In terms of profitability, MYGN's ROE is -0.14%, compared to DGX's ROE of +0.14%. Regarding short-term risk, MYGN is more volatile compared to DGX. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check DGX's competition here
MYGN vs WAT Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, WAT has a market cap of 18B. Regarding current trading prices, MYGN is priced at $4.38, while WAT trades at $302.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas WAT's P/E ratio is 27.42. In terms of profitability, MYGN's ROE is -0.14%, compared to WAT's ROE of +0.39%. Regarding short-term risk, MYGN is more volatile compared to WAT. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check WAT's competition here
MYGN vs ILMN Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, ILMN has a market cap of 17.4B. Regarding current trading prices, MYGN is priced at $4.38, while ILMN trades at $109.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas ILMN's P/E ratio is -18.07. In terms of profitability, MYGN's ROE is -0.14%, compared to ILMN's ROE of -0.46%. Regarding short-term risk, MYGN is more volatile compared to ILMN. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check ILMN's competition here
MYGN vs ICLR Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, ICLR has a market cap of 15.3B. Regarding current trading prices, MYGN is priced at $4.38, while ICLR trades at $189.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas ICLR's P/E ratio is 19.53. In terms of profitability, MYGN's ROE is -0.14%, compared to ICLR's ROE of +0.08%. Regarding short-term risk, MYGN is more volatile compared to ICLR. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check ICLR's competition here
MYGN vs PKI Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, MYGN is priced at $4.38, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas PKI's P/E ratio is 41.45. In terms of profitability, MYGN's ROE is -0.14%, compared to PKI's ROE of +0.04%. Regarding short-term risk, MYGN is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check PKI's competition here
MYGN vs MEDP Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, MEDP has a market cap of 12.7B. Regarding current trading prices, MYGN is priced at $4.38, while MEDP trades at $453.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas MEDP's P/E ratio is 33.63. In terms of profitability, MYGN's ROE is -0.14%, compared to MEDP's ROE of +0.68%. Regarding short-term risk, MYGN is more volatile compared to MEDP. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check MEDP's competition here
MYGN vs RVTY Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, RVTY has a market cap of 11.2B. Regarding current trading prices, MYGN is priced at $4.38, while RVTY trades at $95.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas RVTY's P/E ratio is 39.27. In terms of profitability, MYGN's ROE is -0.14%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, MYGN is less volatile compared to RVTY. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check RVTY's competition here
MYGN vs QGEN Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, QGEN has a market cap of 11B. Regarding current trading prices, MYGN is priced at $4.38, while QGEN trades at $50.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas QGEN's P/E ratio is 118.63. In terms of profitability, MYGN's ROE is -0.14%, compared to QGEN's ROE of +0.03%. Regarding short-term risk, MYGN is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check QGEN's competition here
MYGN vs TEM Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, TEM has a market cap of 10.4B. Regarding current trading prices, MYGN is priced at $4.38, while TEM trades at $62.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas TEM's P/E ratio is -12.02. In terms of profitability, MYGN's ROE is -0.14%, compared to TEM's ROE of -5.31%. Regarding short-term risk, MYGN is less volatile compared to TEM. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check TEM's competition here
MYGN vs EXAS Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, EXAS has a market cap of 9.1B. Regarding current trading prices, MYGN is priced at $4.38, while EXAS trades at $48.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas EXAS's P/E ratio is -8.69. In terms of profitability, MYGN's ROE is -0.14%, compared to EXAS's ROE of -0.36%. Regarding short-term risk, MYGN is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check EXAS's competition here
MYGN vs CRL Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, CRL has a market cap of 8.8B. Regarding current trading prices, MYGN is priced at $4.38, while CRL trades at $178.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas CRL's P/E ratio is -298.38. In terms of profitability, MYGN's ROE is -0.14%, compared to CRL's ROE of -0.01%. Regarding short-term risk, MYGN is more volatile compared to CRL. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check CRL's competition here
MYGN vs GH Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, GH has a market cap of 5.5B. Regarding current trading prices, MYGN is priced at $4.38, while GH trades at $44.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas GH's P/E ratio is -13.06. In terms of profitability, MYGN's ROE is -0.14%, compared to GH's ROE of +3.69%. Regarding short-term risk, MYGN is more volatile compared to GH. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check GH's competition here
MYGN vs SYNH Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, MYGN is priced at $4.38, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas SYNH's P/E ratio is 61.40. In terms of profitability, MYGN's ROE is -0.14%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, MYGN is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check SYNH's competition here
MYGN vs RDNT Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, RDNT has a market cap of 4.4B. Regarding current trading prices, MYGN is priced at $4.38, while RDNT trades at $57.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas RDNT's P/E ratio is -134.49. In terms of profitability, MYGN's ROE is -0.14%, compared to RDNT's ROE of +0.03%. Regarding short-term risk, MYGN is more volatile compared to RDNT. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check RDNT's competition here
MYGN vs SHC Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, SHC has a market cap of 3.5B. Regarding current trading prices, MYGN is priced at $4.38, while SHC trades at $12.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas SHC's P/E ratio is 136.56. In terms of profitability, MYGN's ROE is -0.14%, compared to SHC's ROE of +0.06%. Regarding short-term risk, MYGN is more volatile compared to SHC. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check SHC's competition here
MYGN vs OLK Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, MYGN is priced at $4.38, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas OLK's P/E ratio is -96.59. In terms of profitability, MYGN's ROE is -0.14%, compared to OLK's ROE of -0.07%. Regarding short-term risk, MYGN is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check OLK's competition here
MYGN vs TWST Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, TWST has a market cap of 2.2B. Regarding current trading prices, MYGN is priced at $4.38, while TWST trades at $36.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas TWST's P/E ratio is -11.24. In terms of profitability, MYGN's ROE is -0.14%, compared to TWST's ROE of -0.41%. Regarding short-term risk, MYGN is less volatile compared to TWST. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check TWST's competition here
MYGN vs VIVO Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, VIVO has a market cap of 1.5B. Regarding current trading prices, MYGN is priced at $4.38, while VIVO trades at $33.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas VIVO's P/E ratio is 21.09. In terms of profitability, MYGN's ROE is -0.14%, compared to VIVO's ROE of +0.12%. Regarding short-term risk, MYGN is more volatile compared to VIVO. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check VIVO's competition here
MYGN vs GRAL Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, GRAL has a market cap of 1.4B. Regarding current trading prices, MYGN is priced at $4.38, while GRAL trades at $38.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas GRAL's P/E ratio is -0.64. In terms of profitability, MYGN's ROE is -0.14%, compared to GRAL's ROE of -0.75%. Regarding short-term risk, MYGN is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check GRAL's competition here
MYGN vs NEOG Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, NEOG has a market cap of 1.2B. Regarding current trading prices, MYGN is priced at $4.38, while NEOG trades at $5.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas NEOG's P/E ratio is -2.43. In terms of profitability, MYGN's ROE is -0.14%, compared to NEOG's ROE of -0.17%. Regarding short-term risk, MYGN is less volatile compared to NEOG. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check NEOG's competition here
MYGN vs OPK Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, OPK has a market cap of 1.1B. Regarding current trading prices, MYGN is priced at $4.38, while OPK trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas OPK's P/E ratio is -22.50. In terms of profitability, MYGN's ROE is -0.14%, compared to OPK's ROE of -0.03%. Regarding short-term risk, MYGN is more volatile compared to OPK. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check OPK's competition here
MYGN vs CDNA Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, CDNA has a market cap of 712.2M. Regarding current trading prices, MYGN is priced at $4.38, while CDNA trades at $12.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas CDNA's P/E ratio is 11.42. In terms of profitability, MYGN's ROE is -0.14%, compared to CDNA's ROE of +0.18%. Regarding short-term risk, MYGN is more volatile compared to CDNA. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check CDNA's competition here
MYGN vs GRALV Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, MYGN is priced at $4.38, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas GRALV's P/E ratio is N/A. In terms of profitability, MYGN's ROE is -0.14%, compared to GRALV's ROE of N/A. Regarding short-term risk, MYGN is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check GRALV's competition here
MYGN vs FLGT Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, FLGT has a market cap of 548.6M. Regarding current trading prices, MYGN is priced at $4.38, while FLGT trades at $18.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas FLGT's P/E ratio is -13.55. In terms of profitability, MYGN's ROE is -0.14%, compared to FLGT's ROE of -0.04%. Regarding short-term risk, MYGN is more volatile compared to FLGT. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check FLGT's competition here
MYGN vs PSNL Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, PSNL has a market cap of 543.2M. Regarding current trading prices, MYGN is priced at $4.38, while PSNL trades at $6.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas PSNL's P/E ratio is -4.77. In terms of profitability, MYGN's ROE is -0.14%, compared to PSNL's ROE of -0.49%. Regarding short-term risk, MYGN is less volatile compared to PSNL. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check PSNL's competition here
MYGN vs LAB Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, LAB has a market cap of 539.3M. Regarding current trading prices, MYGN is priced at $4.38, while LAB trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas LAB's P/E ratio is -4.44. In terms of profitability, MYGN's ROE is -0.14%, compared to LAB's ROE of -0.28%. Regarding short-term risk, MYGN is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check LAB's competition here
MYGN vs CSTL Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, CSTL has a market cap of 471.5M. Regarding current trading prices, MYGN is priced at $4.38, while CSTL trades at $16.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas CSTL's P/E ratio is -85.95. In terms of profitability, MYGN's ROE is -0.14%, compared to CSTL's ROE of -0.01%. Regarding short-term risk, MYGN is more volatile compared to CSTL. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check CSTL's competition here
MYGN vs CO Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, MYGN is priced at $4.38, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas CO's P/E ratio is 5.06. In terms of profitability, MYGN's ROE is -0.14%, compared to CO's ROE of +0.11%. Regarding short-term risk, MYGN is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check CO's competition here
MYGN vs STIM Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, STIM has a market cap of 298.8M. Regarding current trading prices, MYGN is priced at $4.38, while STIM trades at $4.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas STIM's P/E ratio is -3.42. In terms of profitability, MYGN's ROE is -0.14%, compared to STIM's ROE of -2.09%. Regarding short-term risk, MYGN is more volatile compared to STIM. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check STIM's competition here
MYGN vs FLDM Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, MYGN is priced at $4.38, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas FLDM's P/E ratio is -4.74. In terms of profitability, MYGN's ROE is -0.14%, compared to FLDM's ROE of -0.28%. Regarding short-term risk, MYGN is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check FLDM's competition here
MYGN vs ACRS Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, ACRS has a market cap of 183M. Regarding current trading prices, MYGN is priced at $4.38, while ACRS trades at $1.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas ACRS's P/E ratio is -1.06. In terms of profitability, MYGN's ROE is -0.14%, compared to ACRS's ROE of -0.92%. Regarding short-term risk, MYGN is less volatile compared to ACRS. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check ACRS's competition here
MYGN vs NEO Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, NEO has a market cap of 166.5M. Regarding current trading prices, MYGN is priced at $4.38, while NEO trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas NEO's P/E ratio is -10.61. In terms of profitability, MYGN's ROE is -0.14%, compared to NEO's ROE of -0.09%. Regarding short-term risk, MYGN is less volatile compared to NEO. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check NEO's competition here
MYGN vs XGN Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, XGN has a market cap of 161.5M. Regarding current trading prices, MYGN is priced at $4.38, while XGN trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas XGN's P/E ratio is -8.80. In terms of profitability, MYGN's ROE is -0.14%, compared to XGN's ROE of -1.34%. Regarding short-term risk, MYGN is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check XGN's competition here
MYGN vs GTH Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, MYGN is priced at $4.38, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas GTH's P/E ratio is -1.11. In terms of profitability, MYGN's ROE is -0.14%, compared to GTH's ROE of -1.01%. Regarding short-term risk, MYGN is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check GTH's competition here
MYGN vs MDXH Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, MDXH has a market cap of 125.7M. Regarding current trading prices, MYGN is priced at $4.38, while MDXH trades at $2.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas MDXH's P/E ratio is -2.44. In terms of profitability, MYGN's ROE is -0.14%, compared to MDXH's ROE of -5.35%. Regarding short-term risk, MYGN is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check MDXH's competition here
MYGN vs SERA Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, SERA has a market cap of 115.3M. Regarding current trading prices, MYGN is priced at $4.38, while SERA trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas SERA's P/E ratio is -3.34. In terms of profitability, MYGN's ROE is -0.14%, compared to SERA's ROE of -0.51%. Regarding short-term risk, MYGN is more volatile compared to SERA. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check SERA's competition here
MYGN vs GENE Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, MYGN is priced at $4.38, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas GENE's P/E ratio is -38.25. In terms of profitability, MYGN's ROE is -0.14%, compared to GENE's ROE of -3.62%. Regarding short-term risk, MYGN is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check GENE's competition here
MYGN vs ATLN Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, ATLN has a market cap of 107.3M. Regarding current trading prices, MYGN is priced at $4.38, while ATLN trades at $1.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas ATLN's P/E ratio is -0.47. In terms of profitability, MYGN's ROE is -0.14%, compared to ATLN's ROE of -42.96%. Regarding short-term risk, MYGN is less volatile compared to ATLN. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check ATLN's competition here
MYGN vs PRE Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, PRE has a market cap of 105.4M. Regarding current trading prices, MYGN is priced at $4.38, while PRE trades at $8.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas PRE's P/E ratio is -2.12. In terms of profitability, MYGN's ROE is -0.14%, compared to PRE's ROE of -0.28%. Regarding short-term risk, MYGN is more volatile compared to PRE. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check PRE's competition here
MYGN vs PRENW Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, PRENW has a market cap of 90.5M. Regarding current trading prices, MYGN is priced at $4.38, while PRENW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas PRENW's P/E ratio is N/A. In terms of profitability, MYGN's ROE is -0.14%, compared to PRENW's ROE of -0.28%. Regarding short-term risk, MYGN is more volatile compared to PRENW. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check PRENW's competition here
MYGN vs VNRX Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, VNRX has a market cap of 75.9M. Regarding current trading prices, MYGN is priced at $4.38, while VNRX trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas VNRX's P/E ratio is -2.70. In terms of profitability, MYGN's ROE is -0.14%, compared to VNRX's ROE of +1.08%. Regarding short-term risk, MYGN is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check VNRX's competition here
MYGN vs NOTV Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, NOTV has a market cap of 73.9M. Regarding current trading prices, MYGN is priced at $4.38, while NOTV trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas NOTV's P/E ratio is -0.69. In terms of profitability, MYGN's ROE is -0.14%, compared to NOTV's ROE of -0.51%. Regarding short-term risk, MYGN is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check NOTV's competition here
MYGN vs BDSX Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, BDSX has a market cap of 61.1M. Regarding current trading prices, MYGN is priced at $4.38, while BDSX trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas BDSX's P/E ratio is -1.54. In terms of profitability, MYGN's ROE is -0.14%, compared to BDSX's ROE of -1.68%. Regarding short-term risk, MYGN is less volatile compared to BDSX. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check BDSX's competition here
MYGN vs STRRP Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, STRRP has a market cap of 29.1M. Regarding current trading prices, MYGN is priced at $4.38, while STRRP trades at $9.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas STRRP's P/E ratio is -4.52. In terms of profitability, MYGN's ROE is -0.14%, compared to STRRP's ROE of -0.24%. Regarding short-term risk, MYGN is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check STRRP's competition here
MYGN vs DRIO Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, DRIO has a market cap of 27.8M. Regarding current trading prices, MYGN is priced at $4.38, while DRIO trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas DRIO's P/E ratio is -1.14. In terms of profitability, MYGN's ROE is -0.14%, compared to DRIO's ROE of -0.17%. Regarding short-term risk, MYGN is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check DRIO's competition here
MYGN vs AKU Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, MYGN is priced at $4.38, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas AKU's P/E ratio is -0.13. In terms of profitability, MYGN's ROE is -0.14%, compared to AKU's ROE of -5.32%. Regarding short-term risk, MYGN is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check AKU's competition here
MYGN vs PRPO Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, PRPO has a market cap of 22M. Regarding current trading prices, MYGN is priced at $4.38, while PRPO trades at $14.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas PRPO's P/E ratio is -7.05. In terms of profitability, MYGN's ROE is -0.14%, compared to PRPO's ROE of -0.26%. Regarding short-term risk, MYGN is less volatile compared to PRPO. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check PRPO's competition here
MYGN vs CEMI Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, MYGN is priced at $4.38, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas CEMI's P/E ratio is -0.63. In terms of profitability, MYGN's ROE is -0.14%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, MYGN is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check CEMI's competition here
MYGN vs ENZ Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, MYGN is priced at $4.38, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas ENZ's P/E ratio is -2.24. In terms of profitability, MYGN's ROE is -0.14%, compared to ENZ's ROE of -0.44%. Regarding short-term risk, MYGN is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check ENZ's competition here
MYGN vs PMD Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, PMD has a market cap of 15.7M. Regarding current trading prices, MYGN is priced at $4.38, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas PMD's P/E ratio is -5.24. In terms of profitability, MYGN's ROE is -0.14%, compared to PMD's ROE of -0.33%. Regarding short-term risk, MYGN is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check PMD's competition here
MYGN vs ME Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, ME has a market cap of 13.3M. Regarding current trading prices, MYGN is priced at $4.38, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas ME's P/E ratio is -0.03. In terms of profitability, MYGN's ROE is -0.14%, compared to ME's ROE of -3.99%. Regarding short-term risk, MYGN is less volatile compared to ME. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check ME's competition here
MYGN vs ADVB Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, ADVB has a market cap of 11.5M. Regarding current trading prices, MYGN is priced at $4.38, while ADVB trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas ADVB's P/E ratio is -3.33. In terms of profitability, MYGN's ROE is -0.14%, compared to ADVB's ROE of -1.86%. Regarding short-term risk, MYGN is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check ADVB's competition here
MYGN vs BNGO Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, BNGO has a market cap of 11M. Regarding current trading prices, MYGN is priced at $4.38, while BNGO trades at $3.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas BNGO's P/E ratio is -0.06. In terms of profitability, MYGN's ROE is -0.14%, compared to BNGO's ROE of -1.57%. Regarding short-term risk, MYGN is less volatile compared to BNGO. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check BNGO's competition here
MYGN vs INBS Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, INBS has a market cap of 10.6M. Regarding current trading prices, MYGN is priced at $4.38, while INBS trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas INBS's P/E ratio is -1.15. In terms of profitability, MYGN's ROE is -0.14%, compared to INBS's ROE of -1.72%. Regarding short-term risk, MYGN is less volatile compared to INBS. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check INBS's competition here
MYGN vs BIAFW Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, BIAFW has a market cap of 10.4M. Regarding current trading prices, MYGN is priced at $4.38, while BIAFW trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas BIAFW's P/E ratio is N/A. In terms of profitability, MYGN's ROE is -0.14%, compared to BIAFW's ROE of -3.68%. Regarding short-term risk, MYGN is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check BIAFW's competition here
MYGN vs BIAF Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, BIAF has a market cap of 9.6M. Regarding current trading prices, MYGN is priced at $4.38, while BIAF trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas BIAF's P/E ratio is -0.47. In terms of profitability, MYGN's ROE is -0.14%, compared to BIAF's ROE of -3.68%. Regarding short-term risk, MYGN is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check BIAF's competition here
MYGN vs CNTG Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, MYGN is priced at $4.38, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas CNTG's P/E ratio is -0.23. In terms of profitability, MYGN's ROE is -0.14%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, MYGN is less volatile compared to CNTG. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check CNTG's competition here
MYGN vs BGLC Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, BGLC has a market cap of 8.1M. Regarding current trading prices, MYGN is priced at $4.38, while BGLC trades at $4.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas BGLC's P/E ratio is -3.78. In terms of profitability, MYGN's ROE is -0.14%, compared to BGLC's ROE of -0.24%. Regarding short-term risk, MYGN is less volatile compared to BGLC. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check BGLC's competition here
MYGN vs MYNZ Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, MYNZ has a market cap of 7.5M. Regarding current trading prices, MYGN is priced at $4.38, while MYNZ trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas MYNZ's P/E ratio is -0.09. In terms of profitability, MYGN's ROE is -0.14%, compared to MYNZ's ROE of -22.70%. Regarding short-term risk, MYGN is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check MYNZ's competition here
MYGN vs BNR Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, BNR has a market cap of 7.4M. Regarding current trading prices, MYGN is priced at $4.38, while BNR trades at $6.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas BNR's P/E ratio is -2.14. In terms of profitability, MYGN's ROE is -0.14%, compared to BNR's ROE of -0.39%. Regarding short-term risk, MYGN is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check BNR's competition here
MYGN vs TRIB Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, TRIB has a market cap of 7M. Regarding current trading prices, MYGN is priced at $4.38, while TRIB trades at $0.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas TRIB's P/E ratio is -0.37. In terms of profitability, MYGN's ROE is -0.14%, compared to TRIB's ROE of +1.12%. Regarding short-term risk, MYGN is less volatile compared to TRIB. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check TRIB's competition here
MYGN vs STRR Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, STRR has a market cap of 6.8M. Regarding current trading prices, MYGN is priced at $4.38, while STRR trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas STRR's P/E ratio is -0.71. In terms of profitability, MYGN's ROE is -0.14%, compared to STRR's ROE of -0.24%. Regarding short-term risk, MYGN is less volatile compared to STRR. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check STRR's competition here
MYGN vs NVTA Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, MYGN is priced at $4.38, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas NVTA's P/E ratio is -0.00. In terms of profitability, MYGN's ROE is -0.14%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, MYGN is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check NVTA's competition here
MYGN vs LMDX Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, MYGN is priced at $4.38, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas LMDX's P/E ratio is -0.01. In terms of profitability, MYGN's ROE is -0.14%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, MYGN is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check LMDX's competition here
MYGN vs LMDXW Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, MYGN is priced at $4.38, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, MYGN's ROE is -0.14%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, MYGN is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check LMDXW's competition here
MYGN vs NDRA Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, NDRA has a market cap of 4.7M. Regarding current trading prices, MYGN is priced at $4.38, while NDRA trades at $6.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas NDRA's P/E ratio is 0.02. In terms of profitability, MYGN's ROE is -0.14%, compared to NDRA's ROE of -1.96%. Regarding short-term risk, MYGN is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check NDRA's competition here
MYGN vs CHEK Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, CHEK has a market cap of 4.4M. Regarding current trading prices, MYGN is priced at $4.38, while CHEK trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas CHEK's P/E ratio is -0.35. In terms of profitability, MYGN's ROE is -0.14%, compared to CHEK's ROE of -0.52%. Regarding short-term risk, MYGN is more volatile compared to CHEK. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check CHEK's competition here
MYGN vs DMTK Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, MYGN is priced at $4.38, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas DMTK's P/E ratio is -0.04. In terms of profitability, MYGN's ROE is -0.14%, compared to DMTK's ROE of -0.80%. Regarding short-term risk, MYGN is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check DMTK's competition here
MYGN vs AWH Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, AWH has a market cap of 2.9M. Regarding current trading prices, MYGN is priced at $4.38, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas AWH's P/E ratio is -0.09. In terms of profitability, MYGN's ROE is -0.14%, compared to AWH's ROE of +4.66%. Regarding short-term risk, MYGN is less volatile compared to AWH. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check AWH's competition here
MYGN vs ISPC Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, ISPC has a market cap of 2.8M. Regarding current trading prices, MYGN is priced at $4.38, while ISPC trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas ISPC's P/E ratio is -0.09. In terms of profitability, MYGN's ROE is -0.14%, compared to ISPC's ROE of -2.85%. Regarding short-term risk, MYGN is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check ISPC's competition here
MYGN vs APDN Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, APDN has a market cap of 2.6M. Regarding current trading prices, MYGN is priced at $4.38, while APDN trades at $4.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas APDN's P/E ratio is N/A. In terms of profitability, MYGN's ROE is -0.14%, compared to APDN's ROE of -2.81%. Regarding short-term risk, MYGN is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check APDN's competition here
MYGN vs SQL Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, MYGN is priced at $4.38, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas SQL's P/E ratio is -0.40. In terms of profitability, MYGN's ROE is -0.14%, compared to SQL's ROE of +10.89%. Regarding short-term risk, MYGN is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check SQL's competition here
MYGN vs HTGM Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, MYGN is priced at $4.38, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas HTGM's P/E ratio is -0.03. In terms of profitability, MYGN's ROE is -0.14%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, MYGN is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check HTGM's competition here
MYGN vs TTOO Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, TTOO has a market cap of 701.1K. Regarding current trading prices, MYGN is priced at $4.38, while TTOO trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas TTOO's P/E ratio is -0.83. In terms of profitability, MYGN's ROE is -0.14%, compared to TTOO's ROE of +2.06%. Regarding short-term risk, MYGN is less volatile compared to TTOO. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check TTOO's competition here
MYGN vs BIOC Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, MYGN is priced at $4.38, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas BIOC's P/E ratio is -0.01. In terms of profitability, MYGN's ROE is -0.14%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, MYGN is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check BIOC's competition here
MYGN vs OPGN Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, OPGN has a market cap of 392.7K. Regarding current trading prices, MYGN is priced at $4.38, while OPGN trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas OPGN's P/E ratio is N/A. In terms of profitability, MYGN's ROE is -0.14%, compared to OPGN's ROE of +1.20%. Regarding short-term risk, MYGN is less volatile compared to OPGN. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check OPGN's competition here
MYGN vs SQLLW Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, SQLLW has a market cap of 117.9K. Regarding current trading prices, MYGN is priced at $4.38, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, MYGN's ROE is -0.14%, compared to SQLLW's ROE of -42.96%. Regarding short-term risk, MYGN is more volatile compared to SQLLW. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check SQLLW's competition here
MYGN vs OCDX Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, MYGN is priced at $4.38, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas OCDX's P/E ratio is -42.28. In terms of profitability, MYGN's ROE is -0.14%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, MYGN is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check OCDX's competition here
MYGN vs MEUSW Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, MYGN is priced at $4.38, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas MEUSW's P/E ratio is N/A. In terms of profitability, MYGN's ROE is -0.14%, compared to MEUSW's ROE of -3.99%. Regarding short-term risk, MYGN is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for MYGN.Check MEUSW's competition here
MYGN vs DHR-PA Comparison July 2025
MYGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MYGN stands at 403.7M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, MYGN is priced at $4.38, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MYGN currently has a P/E ratio of -3.91, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, MYGN's ROE is -0.14%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, MYGN is more volatile compared to DHR-PA. This indicates potentially higher risk in terms of short-term price fluctuations for MYGN.Check DHR-PA's competition here